Major
Acetylsalicylic acid × Spironolactone
Antiplatelet agents (low dose) / NSAIDs (analgesic dose)×Potassium-sparing diuretics (mineralocorticoid receptor antagonists)
Mechanism
Aspirin suppresses renal prostaglandin synthesis that maintains glomerular perfusion. Diuretic and natriuretic effects of spironolactone diminish and potassium accumulates.
Symptoms
Oedema, weight gain, rising blood pressure. Weakness, paraesthesia, and arrhythmias from hyperkalaemia. Reduced diuretic effect emerges within 1–2 weeks of starting aspirin.
Management
At low aspirin doses (75–100 mg for cardioprotection), the clinical effect is minimal; co-prescription is acceptable with potassium and creatinine monitoring. At full anti-inflammatory doses, the diuretic response drops markedly – titrate spironolactone clinically.
Sources
- ESC: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure (2021)– Eur Heart J 2021;42(36):3599–3726
- FDA: FDA Drug Safety Communication: FDA strengthens warning that non-aspirin NSAIDs can cause heart attacks or strokes (2015)– FDA Drug Safety Communication, July 9, 2015
- ESC: 2023 Focused Update of the 2021 ESC Guidelines for the treatment of heart failure (2023)– Eur Heart J 2023;44(37):3627–3639
- AHA: Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association (2016)– Circulation 2016;134(6):e32–e69